Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GALT NASDAQ:GLSI NASDAQ:LTRN NASDAQ:RAPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGALTGalectin Therapeutics$2.80-3.1%$1.85$0.73▼$3.90$177.21M0.7419,594 shs443,638 shsGLSIGreenwich LifeSciences$11.59-5.8%$9.73$8.06▼$17.00$154.96M1.6346,335 shs154,544 shsLTRNLantern Pharma$3.99-6.8%$3.39$2.55▼$6.12$43.01M1.5482,785 shs172,785 shsRAPTRapt Therapeutics$11.68+14.2%$8.14$5.67▼$29.60$193.19M-0.09167,926 shs162,879 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGALTGalectin Therapeutics+1.40%+17.96%+20.92%+109.42%+12.23%GLSIGreenwich LifeSciences+9.92%+9.63%+36.21%+37.43%-24.21%LTRNLantern Pharma+7.27%+21.94%+35.87%+25.15%-11.39%RAPTRapt Therapeutics-2.76%+18.68%+30.48%+61.76%-64.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGALTGalectin Therapeutics2.2811 of 5 stars3.52.00.00.03.31.70.0GLSIGreenwich LifeSciences2.176 of 5 stars3.50.00.00.03.33.30.0LTRNLantern Pharma3.0133 of 5 stars3.55.00.00.02.30.80.6RAPTRapt Therapeutics4.388 of 5 stars3.14.00.04.22.51.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGALTGalectin Therapeutics 3.00Buy$6.00114.29% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00236.50% UpsideLTRNLantern Pharma 3.00Buy$25.00526.57% UpsideRAPTRapt Therapeutics 2.17Hold$19.8069.52% UpsideCurrent Analyst Ratings BreakdownLatest LTRN, GALT, GLSI, and RAPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.006/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/22/2025RAPTRapt TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.005/22/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$48.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/ALTRNLantern PharmaN/AN/AN/AN/A$1.96 per shareN/ARAPTRapt Therapeutics$1.53M126.27N/AN/A$11.51 per share1.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)GLSIGreenwich LifeSciences-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/13/2025 (Estimated)LTRNLantern Pharma-$20.78M-$1.84N/AN/AN/AN/A-83.26%-70.65%8/6/2025 (Estimated)RAPTRapt Therapeutics-$129.87M-$19.20N/AN/AN/AN/A-81.47%-70.24%8/6/2025 (Estimated)Latest LTRN, GALT, GLSI, and RAPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025LTRNLantern Pharma-$0.53N/AN/AN/AN/AN/A8/14/2025Q2 2025RAPTRapt Therapeutics-$0.68N/AN/AN/AN/AN/A8/13/2025N/AGLSIGreenwich LifeSciences-$0.24N/AN/AN/AN/AN/A8/12/2025Q2 2025GALTGalectin Therapeutics-$0.16N/AN/AN/AN/AN/A5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/15/2025Q1 2025LTRNLantern Pharma-$0.49-$0.42+$0.07-$0.42N/AN/A5/8/2025Q1 2025RAPTRapt Therapeutics-$2.48-$0.64+$1.84-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGALTGalectin TherapeuticsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGALTGalectin TherapeuticsN/A0.080.08GLSIGreenwich LifeSciencesN/A1.911.91LTRNLantern PharmaN/A4.864.86RAPTRapt TherapeuticsN/A21.1121.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGALTGalectin Therapeutics11.68%GLSIGreenwich LifeSciences4.16%LTRNLantern Pharma28.62%RAPTRapt Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipGALTGalectin Therapeutics50.10%GLSIGreenwich LifeSciences51.67%LTRNLantern Pharma7.31%RAPTRapt Therapeutics2.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionableGLSIGreenwich LifeSciences313.37 million6.46 millionNot OptionableLTRNLantern Pharma2010.78 million10.00 millionOptionableRAPTRapt Therapeutics8016.54 million16.15 millionOptionableLTRN, GALT, GLSI, and RAPT HeadlinesRecent News About These CompaniesRapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's WhyJuly 15 at 4:19 PM | msn.comRapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's WhyJuly 15 at 1:01 PM | zacks.comAegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the BoardJuly 15 at 11:18 AM | tmcnet.comBest Momentum Stocks to Buy for July 15thJuly 15 at 11:01 AM | zacks.comDoes Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?July 15 at 10:56 AM | zacks.comNew Strong Buy Stocks for July 15thJuly 15 at 6:56 AM | zacks.comHC Wainwright Forecasts Lower Earnings for Rapt TherapeuticsJuly 15 at 2:15 AM | americanbankingnews.comHC Wainwright Analysts Decrease Earnings Estimates for RAPTJuly 14, 2025 | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Price Target Raised to $27.00July 13, 2025 | americanbankingnews.comHC Wainwright Forecasts Strong Price Appreciation for Rapt Therapeutics (NASDAQ:RAPT) StockJuly 10, 2025 | marketbeat.comRAPT Therapeutics Inc.July 5, 2025 | barrons.comRAPT Therapeutics Inc Ordinary Shares - MorningstarJuly 3, 2025 | morningstar.comMRapt Therapeutics (NASDAQ:RAPT) Given Average Rating of "Hold" by AnalystsJune 28, 2025 | marketbeat.comRAPT Therapeutics expands board with two new directorsJune 25, 2025 | investing.comRAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of Directors - NasdaqJune 25, 2025 | nasdaq.comRAPT Therapeutics Names Two Industry Veterans to its Board of DirectorsJune 23, 2025 | globenewswire.comRapt Therapeutics (NASDAQ:RAPT) Lowered to Sell Rating by Wall Street ZenJune 21, 2025 | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Shares Gap Down - Time to Sell?June 18, 2025 | marketbeat.comWall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should KnowJune 18, 2025 | zacks.comRAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025June 15, 2025 | nasdaq.comRAPT Therapeutics, Inc. Announces 1-for-8 Reverse Stock Split Effective June 16, 2025June 15, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTRN, GALT, GLSI, and RAPT Company DescriptionsGalectin Therapeutics NASDAQ:GALT$2.80 -0.09 (-3.11%) Closing price 04:00 PM EasternExtended Trading$2.99 +0.19 (+6.75%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Greenwich LifeSciences NASDAQ:GLSI$11.59 -0.71 (-5.77%) Closing price 04:00 PM EasternExtended Trading$11.62 +0.03 (+0.22%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Lantern Pharma NASDAQ:LTRN$3.99 -0.29 (-6.78%) Closing price 04:00 PM EasternExtended Trading$3.92 -0.07 (-1.73%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Rapt Therapeutics NASDAQ:RAPT$11.68 +1.45 (+14.17%) Closing price 04:00 PM EasternExtended Trading$11.45 -0.23 (-1.98%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
